Terumo (OTCMKTS:TRUMY) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Terumo (OTCMKTS:TRUMY) released its quarterly earnings results on Thursday. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06), Zacks reports. Terumo had a net margin of 13.83% and a return on equity of 10.44%.

Terumo Trading Down 7.0%

Shares of Terumo stock traded down $1.10 during trading on Thursday, hitting $14.68. The company’s stock had a trading volume of 40,096 shares, compared to its average volume of 233,838. The stock has a market cap of $21.65 billion, a price-to-earnings ratio of 20.68 and a beta of 0.82. Terumo has a 52 week low of $12.08 and a 52 week high of $16.81. The stock has a 50-day moving average price of $14.83 and a two-hundred day moving average price of $14.08. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.19 and a quick ratio of 1.37.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on TRUMY shares. Nomura raised shares of Terumo from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. Zacks Research upgraded Terumo from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 13th. Two analysts have rated the stock with a Strong Buy rating. According to MarketBeat.com, Terumo presently has an average rating of “Strong Buy”.

Terumo Company Profile

Terumo Corporation is a Japan-based medical technology company that develops and manufactures products for hospitals, clinics and other healthcare providers. Founded in 1921, the company began by producing clinical thermometers and has since expanded into a broad range of medical devices and services. Terumo’s businesses include cardiovascular and vascular products, such as catheter-based devices and systems used in the treatment of heart and vascular conditions; medical care products, including infusion and injection devices; and blood and cell technologies used to collect, process and manage blood and cellular therapies.